<DOC>
	<DOCNO>NCT02226172</DOCNO>
	<brief_summary>A lead-in cohort ~20 patient primary secondary myelofibrosis previously treat 1 Janus kinase inhibitor enrol single-agent glasdegib evaluate safety tolerability . Following lead-in , phase 2 , double blind , 2-arm study , randomize 2:1 oral single-agent glasdegib versus placebo 201 patient resistant intolerant ruxolitinib .</brief_summary>
	<brief_title>Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Inclusion criterion : Diagnosis primary MF ( PMF ) secondary MF ( PETMF PPVMF ) per WHO 2008 criterion . Leadin cohort : resistant intolerant 1 Janus kinase inhibitor ( licensed experimental ) . Randomized cohort : resistant intolerant prior ruxolitinib therapy . Documentation Investigator patient exhaust available treatment option ( eg , resistant intolerant hydroxyurea , etc ) . Spleen 5 cm inferior leave costal margin measure manual palpation . Active symptomatic MF define screen MPNSAD patientreported instrument require severity score least 5 one symptom , severity score â‰¥ 3 least two symptom ( 0 10 scale ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 , 3 . Adequate organ function , demonstrate follow laboratory value : 1 . Absolute Neutrophil Count 75 x 10 ( 9 ) /L ; 2 . Platelet count &gt; 50 x 10 ( 9 ) /L evidence bleed require platelet transfusion ; 3 . Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) estimate creatinine clearance 60 mL/min ( calculate use standard method institution ) ; 4 . Serum amylase lipase &lt; 1.5 x ULN ; 5 . Aspartate aminotransferase alanine aminotransferase value 3.0 x ULN ( 5x ULN case patient MF accompany hepatic extramedullary hematopoiesis , manifest degree hepatomegaly ) . 6 . Total bilirubin value &lt; 1.5 x ULN unless bilirubin principally unconjugated ( context hemolysis ) document Gilbert 's disease . 7 . Serum electrolyte value &lt; Grade 2 ( sodium , potassium , calcium , phosphorous magnesium ) , per CTCAE v.4.03 . Recovery Grade 1 clinically significant adverse event related prior MF therapy , include transplantrelated toxicity . More 2 month allogenic hematopoietic stem cell transplant prior randomization . Must able undergo MRI abdomen ( spleen liver ) . Patients contra indicated MRI may enrol evaluate CT scan discretion Sponsor . 18 year age . Male subject able father child female patient childbearing potential risk pregnancy must agree use two highly effective method contraception throughout study 90 day last dose assign treatment . Exclusion criterion : Prior treatment license experimental smoothened inhibitor . Randomized cohort : Prior treatment Janus kinase inhibitor ruxolitinib . Other anticancer therapy 14 day prior enrollment , exception hydroxyurea , give 4 day prior enrollment . Splenic irradiation 3 month prior enrollment . History congenital long QT syndrome , baseline &gt; 470 msec QTcF abnormality ( average triplicate reading ) . Evidence significant cardiac disease , example : symptomatic cardiac heart failure ( CHF , NYHA class 3 ) , complete bundle branch block , significant atrial ventricular tachyarrhythmias unstable cardiac arrhythmia require medication . History myocardial infarction unstable angina within 6 month prior enrollment . Uncontrolled inflammatory bowel disease , peptic ulcer disease history significant gastro intestinal bleeding within 6 month enrollment . Any condition require chronic use moderate/high dose steroid ( equivalent 10 mg QD prednisone ) . Hematopoietic growth factor receptor agonist ( eg , erythropoietin ( Epo ) , granulocyte colony stimulate factor , romiplostim , eltrombopag within 28 day enrollment . Currently active malignancy ( MF ) . Prior malignancy allow long evidence disease recurrence within last 2 year ( exception fully excise , noncomplicated basal cell carcinoma active within prior 2 year , certain localize , noninvasive fully excise skin , cervical , breast , prostate bladder tumor ) . Prior history chronic liver disease ( eg , chronic alcoholic liver disease , autoimmune hepatitis , sclerosing cholangitis , primary biliary cirrhosis , hemachromatosis , nonalcoholic steatohepatitis [ NASH ] ) . Active , uncontrolled bacterial , fungal viral infection , include hepatitis B , hepatitis C , know human immunodeficiency virus acquire immunodeficiency syndrome related illness . Active graft versus host disease ( GVHD ) grade 1 skin involvement GVHD require immunosuppressive treatment . Uncontrolled disseminate intravascular coagulation . Current ( include administration within 3 day prior study entry ) use anticipate need food drug strong CYP3A4 inhibitor . Current use anticipate requirement drug know strong CYP3A4/5 inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Primary myelofibrosis</keyword>
	<keyword>Secondary myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>PET-MF</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>Ruxolitinib resistant intolerant</keyword>
	<keyword>previously treat myelofibrosis</keyword>
	<keyword>smoothen inhibitor</keyword>
	<keyword>oral</keyword>
	<keyword>single agent .</keyword>
</DOC>